Conditions: Biliary Tract Cancer; Cholangiocarcinoma; Gallbladder Cancer
Intervention:
Sponsor: Herlev and Gentofte Hospital
Recruiting
Feeds
3807 items (3807 unread) in 74 feeds
Acinar Cell Carcinoma
(40 unread)
Acinic Cell Carcinoma
(50 unread)
Adenoid Cystic Carcinoma
(96 unread)
Adrenal Gland Cancer
(350 unread)
Ampulla Of Vater
(53 unread)
Anal Cancer
(367 unread)
Angiosarcoma
(88 unread)
Appendix Cancer
(50 unread)
Bile Duct Cancer
(400 unread)
Brain and CNS
(353 unread)
Carcinoid
(144 unread)
Endocrine/Neuroendocrine
(453 unread)
Gall Bladder Cancer
(301 unread)
Hemangioendothelioma
(90 unread)
Hepatoblastoma
(50 unread)
Pancreas
(28 unread)
Phyllodes
(17 unread)
PMP and Mucinous Tumors
(22 unread)
Rhabdomyosarcoma
(212 unread)
Sarcoma
(643 unread)
Trial - Cholangiocarcinoma (8 unread)
-
Identification of New Biomarkers for Patients With Cholangiocarcinoma and Gallbladder Cancer
Posted: January 11th, 2022, 3:00pm GMT
-
Registry for Advanced Endoscopy
Posted: January 11th, 2022, 3:00pm GMT
Conditions: Cholangiocarcinoma; Pancreatic Cancer; Sclerosing Cholangitis
Interventions: Procedure: Endoscopic retrograde Cholangio- pancreatography; Procedure: Endoscopic ultrasound
Sponsors: Region Stockholm; Karolinska Institutet
Not yet recruiting -
Research Trial to Study Safety of GEN1047 (DuoBody®-CD3xB7H4) in Participants With Malignant Solid Tumors
Posted: January 6th, 2022, 3:00pm GMT
Conditions: Breast Cancer; Uterine Cancer; Ovarian Cancer; Non Small Cell Lung Cancer (NSCLC); Cervical Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC), Except for Nasopharyngeal Carcinoma; Urothelial Cancer; Cholangiocarcinoma (CCA)
Intervention: Biological: GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive cells.
Sponsor: Genmab
Recruiting -
Molecular Epidemiology of Biliary Tree Cancers
Posted: January 5th, 2022, 3:00pm GMT
Conditions: Cholangiocarcinoma; Malignant Digestive System Neoplasm
Interventions: Procedure: Biospecimen Collection; Other: Questionnaire Administration
Sponsor: M.D. Anderson Cancer Center
Recruiting -
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
Posted: January 4th, 2022, 3:00pm GMT
Conditions: Neoplasms; Neoplasm Metastasis; Metastatic Gastrointestinal Carcinoid Tumor
Intervention: Drug: EMB-01
Sponsors: Shanghai EpimAb Biotherapeutics Co., Ltd.; Covance
Recruiting -
Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements
Posted: December 31st, 2021, 3:00pm GMT
Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Atezolizumab; Drug: Derazantinib
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Not yet recruiting -
HMPL-453 Tartrate Combined With Chemotherapy or Teriprizumab in Patients With Advanced Solid Tumors
Posted: December 29th, 2021, 3:00pm GMT
Condition: Solid Tumor
Intervention: Drug: HMPL-453
Sponsor: Hutchison Medipharma Limited
Not yet recruiting -
Phase II Trial of Lenvatinib Plus Paclitaxel for Patients With Advanced Biliary Tract Cancer Who Failed to Gemcitabine-based Treatment
Posted: December 28th, 2021, 3:00pm GMT
Condition: Advanced Biliary Tract Cancer
Intervention: Drug: Lenvatinib Pill
Sponsors: National Health Research Institutes, Taiwan; National Cheng-Kung University Hospital; National Taiwan University Hospital; Kaohsiung Medical University Chung-Ho Memorial Hospital; Taipei Veterans General Hospital, Taiwan; Chang Gung Memorial Hospital; China Medical University, Taiwan
Not yet recruiting